Goa Vibrant Summit -2026 to offer African nations investment opportunities in pharma, medtech and other manufacturing sectors ...
US FDA approves Instylla’s Embrace Hydrogel Embolic System for peripheral arterial bleeds: Burlington, Massachusetts Saturday, October 31, 2026, 18:00 Hrs [IST] Instylla, Inc., ...
Asia-Pacific is rapidly gaining importance as a major pillar in global life science innovation: Shashank Deshpande: Seoul, Korea Saturday, October 31, 2026, 13:00 Hrs [IST] Boehri ...
Azenta announces strategic investments to advance the next generation of GENEWIZ gene synthesis capabilities: Burlington, Massachusetts Saturday, October 31, 2026, 15:00 Hrs [IST] ...
Alkermes plc, a global biopharmaceutical company, announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in adult ...
IDMA’s Silver Jubilee Pharmaceutical Analysts’ Convention to focus on AI, digitalisation and future-ready quality systems: Shardul Nautiyal, Mumbai Saturday, October 31, 2026, ...
Pretzel Therapeutics receives UK MHRA authorization to advance PX578 into clinical development in patients to treat POLG-mediated primary mitochondrial disorders: Waltham, Massach ...
Delhi surgeon performs robotic kidney surgery remotely in Andhra Pradesh: Our Bureau, Mumbai Saturday, October 31, 2026, 14:30 Hrs [IST] A surgeon at Rajiv Gandhi Cancer Institute ...
TMR's one-time margin cut fails to keep prices of anti-cancer drugs under effective control, says AIDAN: Our Bureau, New Delhi Saturday, October 31, 2026, 13:45 Hrs [IST] The mark ...
Data on investigational CagriSema in adults with overweight or obesity include the primary results of REDEFINE 9, which tested low doses of CagriSema. In addition, several post-hoc analyses from the ...
TMR price cut data shows measures inadequate to make cancer drugs affordable, says CSO: Our Bureau, New Delhi Saturday, October 31, 2026, 14:15 Hrs [IST] The Trade Margin Rational ...
CereVasc receives US FDA IDE approval to evaluate eShunt System in patients with Alzheimer’s disease
CereVasc receives US FDA IDE approval to evaluate eShunt System in patients with Alzheimer’s disease: Boston Saturday, October 31, 2026, 11:00 Hrs [IST] CereVasc, Inc., a clinic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results